Blog & News
Patient eCademies
Sarcomas are a diverse and relatively rare group of malignant tumors, originating in supportive and connective tissues such as bones, tendons, cartilage, muscle, and fat – the so called “mesenchymal cells”. They only account for slightly more than 1% of all cancer…
Infographics
Infographics translate information into easy-to-understand visuals. Please feel free to use these infographics for your communication. What are sarcomas? Key facts about sarcomas (please download your preferred language: Englisch, French, German) Merken Merken Merken
Our Members
The network only is as strong as its members. SPAEN welcomes every sarcoma, GIST or desmoid patient group and individuals interested in sarcomas worldwide to become part of our network and thus strengthen it. Why join SPAEN? Enjoy information exchange with…
Summary Leiomyosarcoma Research Roundtable 2019
The Leiomyosarcoma Research Roundtable On September 14, 2019, 35 sarcoma experts and researchers assembled at the Sylvester Cancer Center in Miami, Florida, to discuss the current status of treatment and care in leiomyosarcomas (LMS) as well as brainstorm about possible ways to…
Leiomyosarcoma Position Paper published!
As leiomyosarcoma patients are challenged by the development of metastatic disease, effective systemic therapies are the cornerstone of outcome. However, the overall activity of the currently available conventional systemic treatments and the prognosis of patients with advanced or metastatic disease…
WECAN launches “Virtual Meeting Resource Center”
WECAN has launched the “Virtual Meeting Resource Center“, which provides a set of guides, instructions, check lists and templates which should help patient advocates to run successful virtual meetings, general assemblies, webinars, online brainstorming meetings – as the situation on face-to-face…
Dr. George D. Demetri Receives the 2020 David A. Karnofsky Memorial Award
“On behalf of SPAEN, our member organizations and all GIST- and Sarcoma patients, we congratulate Prof. Demetri on this so well-deserved award. We thank Dr. Demetri for his tireless research efforts in a rare group of diseases such as GIST and…
FDA approval for Ripretinib in fourth-line GIST
The company Deciphera Pharmaceuticals announced on May 15 that the U.S. FDA has approved Ripretinib (brandname Quinlock™) for the treatment of adult patients with advanced Gastrointestinal Stromal Tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including Imatinib.…
Fostering Age Inclusive Research: The Accelerate Working Group
SPAEN supports the Accelerate Working Group Research into teenage and young adult cancers has made slower progress than for any other age group. One reason is that many clinical trials exclude patients under eighteen on the basis of…
Now published in the EJC: The Management of Desmoid Tumors Guideline
https://www.ejcancer.com/article/S0959-8049(19)30832-9/fulltext This paper provides an evidence-based, joint global consensus guideline approach to the management of this disease focusing on: molecular genetics, indications for an active treatment, and available systemic therapeutic options. This paper follows a one-day consensus meeting held in Milan,…